Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche 1Q

Pharmaceutical revenues were flat at $8.1 billion (up 8% in local currencies) with Europe/ROW sales down 8%, U.S. sales up 1%, and Japan sales up 58%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 1Q

1Q Revenues: $10.1 billion (-1%)

1Q Earnings: n/a*

Comments: Pharmaceutical revenues were flat at $8.1 billion (up 8% in local currencies) with Europe/ROW sales down 8%, U.S. sales up 1%, and Japan sales up 58%. Sales drivers were Avastin, Herceptin, Tamiflu, MabThera/Rituxan and Lucentis. In the U.S., growth of key products offset lower sales of Tamiflu. Sales by Chugai in Japan increased due to Tamiflu, anticancer medicines, and Actemra, which was approved for RA in Japan in April 2008. In local currencies, global sales of Tamiflu were up 38%; Avastin sales were up 30%; Herceptin sales increased 11%; U.S. sales of Lucentis increased 21%; and overall sales of MabThera/Rituxan rose 6%.

*The company reports earnings only for 1H and FY.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters